Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30.
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The S&P 500, also fell, dropping, 0.11% to 4,394.78.
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose, gaining, 0.43% to 4,524.74.
ProMIS Neurosciences Inc. (NASDAQ: PMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), PMN310, and additional studies that further characterize a computationally-derived AD vaccine <
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P 500, also rose, gaining, 0.31% to 4,519.25.
